On Mar. 30, 2021, CytoDyn announced further results from its CD12 trial of severe-to-critically ill patients with COVID-19. Upon further statistical analysis of the critically ill population (hospitalized patients receiving invasive mechanical ventilation, it was revealed that when leronlimab was added to standard of care, leronlimab decreased mortality at 14 days by 82%. Patients who received leronlimab were over five times more likely to be alive at day 14 than those who received SoC only.